Literature DB >> 27699046

Lower limb lymphedema in lung adenocarcinoma: Two case reports.

Misae Shinoda1, Haruka Akutsu1, Toshihiro Ohtani2, Tomohiro Tamura3, Hiroaki Satoh3.   

Abstract

Breast and gynecological cancers and their treatment may cause lymphedema of the upper and lower extremities, respectively. We herein report the cases of two patients with lung adenocarcinoma who developed lymphedema of the lower extremities. One patient harbored an epidermal growth factor receptor mutation and the other patient harbored an anaplastic lymphoma kinase fusion gene. The patients had developed intra-abdominal lymph node metastases and received several lines of chemotherapy. In both patients, lymphedema in the lower extremities developed >30 months after the initiation of first-line chemotherapy. To the best of our knowledge, these are the first reported cases of lung cancer patients who developed lymphedema in the lower extremities. Although rarely, lymphedema of the lower extremities may develop long after successful therapy with molecular-targeted therapy in advanced lung adenocarcinoma patients with a specific genetic etiological background.

Entities:  

Keywords:  lower limb lymphedema; lung adenocarcinoma

Year:  2016        PMID: 27699046      PMCID: PMC5038511          DOI: 10.3892/mco.2016.988

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  10 in total

Review 1.  Management and future directions in non-small cell lung cancer with known activating mutations.

Authors:  David E Gerber; Leena Gandhi; Daniel B Costa
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

Review 2.  Incidence of breast carcinoma-related lymphedema.

Authors:  J A Petrek; M C Heelan
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

3.  Treatment of advanced non small cell lung cancer.

Authors:  Maria Anna Bareschino; Clorinda Schettino; Antonio Rossi; Paolo Maione; Paola Claudia Sacco; Rosario Zeppa; Cesare Gridelli
Journal:  J Thorac Dis       Date:  2011-06       Impact factor: 2.895

Review 4.  Symptom management in gynecologic malignancies.

Authors:  Carolyn Casey; Lee-may Chen; Michael W Rabow
Journal:  Expert Rev Anticancer Ther       Date:  2011-07       Impact factor: 4.512

Review 5.  Refining the treatment of NSCLC according to histological and molecular subtypes.

Authors:  Anish Thomas; Stephen V Liu; Deepa S Subramaniam; Giuseppe Giaccone
Journal:  Nat Rev Clin Oncol       Date:  2015-05-12       Impact factor: 66.675

6.  Lymphedema after gynecological cancer treatment : prevalence, correlates, and supportive care needs.

Authors:  Vanessa Beesley; Monika Janda; Elizabeth Eakin; Andreas Obermair; Diana Battistutta
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

Review 7.  Breast cancer-related lymphoedema and venepuncture: a review and evidence-based recommendations.

Authors:  Adam D Jakes; Chris Twelves
Journal:  Breast Cancer Res Treat       Date:  2015-11-20       Impact factor: 4.872

Review 8.  Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.

Authors:  Yosuke Togashi; Hidetoshi Hayashi; Kazuhiko Nakagawa; Kazuto Nishio
Journal:  Drug Des Devel Ther       Date:  2014-07-31       Impact factor: 4.162

Review 9.  Methods to improve rehabilitation of patients following breast cancer surgery: a review of systematic reviews.

Authors:  Siew Yim Loh; Aisya Nadia Musa
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-03-11

10.  Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2013-05-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.